Non-invasive PGT-A, or non-invasive preimplantation genetic testing for aneuploidy, is an innovative technique that offers several advantages in IVF programs. While it is a relatively new approach with some limitations, when used properly for a specific group of patients, it can provide significant benefits. In this article, we will explore the concept of non-invasive PGT-A, compare it to traditional PGT-A from embryo biopsy, discuss its indications and what can be diagnosed using this technique, examine its impact on success rates, provide a real patient example, address the potential risks involved, explain the costs associated with non-invasive PGT-A, and answer frequently asked questions.<\/p>\n\n\n\n
\nThe detection of free DNA in the blastocyst culture medium was published a few years ago and was proposed as a tool for non-invasively determining the embryo’s chromosome load. This DNA is released by the embryo into the culture medium during its development in vitro. In recent years, several studies have demonstrated the ability to detect, extract, and amplify DNA from embryo culture medium, especially at the blastocyst stage, and have evaluated its potential clinical application for non-invasive PGT. <\/p>\nElisa Moya Guti\u00e9rrez Embryologist at UR Vistahermosa Alicante<\/a>.<\/cite><\/blockquote>\n\n\n\n
What is a non-invasive PGT-A (preimplantation genetic testing)?<\/h2>\n\n\n\n
Non-invasive PGT-A refers to a method of genetic testing that does not require an invasive biopsy of the embryo. Instead, it analyzes the genetic material released by the developing embryo into the surrounding culture media. This technique is also known by various other names, such as “trophectoderm DNA testing” or “culture medium analysis.”<\/p>\n\n\n\n
Compared to PGT-A from embryo biopsy, non-invasive PGT-A offers several advantages. It eliminates the need for a biopsy procedure, which can be stressful for both the embryo and the patient. It allows for continuous monitoring of embryo development without disruption, potentially improving embryo selection. Additionally, it provides a non-destructive option for genetic testing, enabling the use of embryos that may have otherwise been discarded.<\/p>\n\n\n\n
Non-invasive PGT-A indications<\/h2>\n\n\n\n
The indications for non-invasive PGT-A are similar to those for traditional PGT-A. It is typically recommended for patients undergoing IVF who are at an increased risk of chromosomal abnormalities or have a history of failed implantation, recurrent miscarriage, or advanced maternal age. By identifying chromosomally normal embryos, non-invasive PGT-A can enhance the chances of a successful pregnancy.<\/p>\n\n\n\n
What can be diagnosed via non-invasive PGT-A?<\/h2>\n\n\n\n
Non-invasive PGT-A like it is offered at UR Vistahermosa<\/a> can diagnose various chromosomal abnormalities, including aneuploidies (abnormal numbers of chromosomes), which are the most common cause of repeated implantation failure e.g. with donor eggs<\/a> and miscarriage. By identifying embryos with the correct number of chromosomes, this technique helps select the most viable embryos for transfer, improving the chances of a successful pregnancy.<\/p>\n\n\n\n
Non-invasive PGT-A vs. IVF success rates<\/h2>\n\n\n\n
When it comes to success rates, non-invasive PGT-A has shown promising results in improving the outcomes of IVF. By selecting embryos with a normal chromosomal profile, the chances of implantation and achieving a healthy pregnancy can be significantly enhanced. However, it is important to note that success rates can vary depending on individual patient factors<\/a> and the specific IVF clinic’s expertise.<\/p>\n\n\n\n
Non-invasive PGT-A IVF – patient example<\/h3>\n\n\n\n
To provide a real patient example, let’s consider a couple in their late 30s who have been struggling with multiple failed IVF cycles and recurrent miscarriages. Non-invasive PGT-A was recommended for them, and through the use of this technique, their embryos were screened for chromosomal abnormalities. This allowed the identification and transfer of a chromosomally normal embryo, resulting in a successful pregnancy and the birth of a healthy baby.<\/p>\n\n\n\n
What are the risks?<\/h2>\n\n\n\n
As with any medical procedure, it is essential to be aware of potential risks. Non-invasive PGT-A is generally considered safe, with no direct harm to the embryos. However, there is a small risk of misdiagnosis or mosaicism, where different cells within an embryo have different chromosomal profiles. It is crucial for patients to discuss these risks with their healthcare provider and understand the limitations of the technique.<\/p>\n\n\n\n
Cost of non-invasive PGT-A<\/h3>\n\n\n\n